Among these, sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, owing to their multifaceted actions, have been proposed as valuable agents in the management of AF via their direct and predominantly indirect antiarrhythmic properties [18,19,20]. The gene discussed is SLC5A2; the disease is atrial fibrillation.